Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Naoko Matsuda, Ricardo H. Alvarez, Savitri Krishnamurthy, Jie S. Willey, Xiaoping Wang, Bora Lim, Charla A. Parker, Angela Marx, Gildy Babiera, Daniel J. Booser, James L. Murray, Banu Arun, Abenaa M. Brewster, James M. Reuben, Wendy A. Woodward, Anthony Lucci, Sarah Marie Gainer, Debu Tripathy, Vicente Valero, Naoto T. Ueno
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4241025368